首页
热心肠日报
文献库
产业库
榜单
关于日报
《肠·道》演讲
往期精彩
《肠·道》2024
《肠·道》2023
《肠·道》2022
《肠·道》2021
《肠·道》2020
《肠·道》2019
《肠·道》2018
《肠·道》2017
关于《肠·道》
肠道大会
热心肠大会
热心肠智库
智库专家
专家动态
智库新闻
关于智库
奖学金
年度人物奖
更多
HOPE
会议信息
科学与艺术
学术专刊
R·AI
周刊
热心肠先生
研究院动态
关于我们
搜索
登录
关闭
手机邮箱登录
扫码登录
微信扫描二维码快捷登录
验证成功,将在
3
秒钟后跳转
已超时,请
重试
关闭
二维码登录
手机登录
邮箱登录
+86
+1
+852
+886
+81
+65
+61
+44
获取验证码
登录 / 注册
关闭
二维码登录
手机登录
邮箱登录
获取验证码
登录 / 注册
热心肠智库
专家文章 | 黄鹤
2024
FA
A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation
Gut Microbes, 10.1080/19490976.2024.2316575
CA
A synthetic microbial consortium protects against obesity by regulating vitamin B6 metabolism
Gut Microbes, 10.1080/19490976.2024.2304901
2023
CA
Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2
Front Immunol, 10.3389/fimmu.2023.1275999
CA
Affinity maturation of antibody fragments: A review encompassing the development from random approaches to computational rational optimization
INT J BIOL MACROMOL, 10.1016/j.ijbiomac.2023.125733
CA
Single-cell microfluidics enabled dynamic evaluation of drug combinations on antibiotic resistance bacteria
TALANTA, 10.1016/j.talanta.2023.124814
CA
Synthetic bacterial therapies for intestinal diseases based on quorum-sensing circuits
BIOTECHNOL ADV, 10.1016/j.biotechadv.2023.108142
点击查看热心肠日报解读
2022
CA
Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies
BIOMED PHARMACOTHER, 10.1016/j.biopha.2022.114174
CA
Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
COMPUT STRUCT BIOTEC, 10.1016/j.csbj.2022.12.021
CA
Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
COMPUT STRUCT BIOTEC, 10.1016/j.csbj.2022.12.021
CA
Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
COMPUT STRUCT BIOTEC, 10.1016/j.csbj.2022.12.021
CA
A droplet-based microfluidic approach to isolating functional bacteria from gut microbiota
FCIMB, 10.3389/fcimb.2022.920986
CA
Modeling spatial interaction networks of the gut microbiota
Gut Microbes, 10.1080/19490976.2022.2106103
点击查看热心肠日报解读
CA
Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment
Front Immunol, 10.3389/fimmu.2021.838082
2021
CA
The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease
Front Nutr, 10.3389/fnut.2021.798038
CA
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
Cancer Biol Med, 10.20892/j.issn.2095-3941.2020.0568
CA
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
Cancer Biol Med, 10.20892/j.issn.2095-3941.2020.0568
CA
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
Cancer Biol Med, 10.20892/j.issn.2095-3941.2020.0568
CA
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
Cancer Biol Med, 10.20892/j.issn.2095-3941.2020.0568
CA
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
Cancer Biol Med, 10.20892/j.issn.2095-3941.2020.0568
CA
Current Status of Mining, Modification, and Application of Cellulases in Bioactive Substance Extraction
CIMB, 10.3390/cimb43020050